ABC008-IBM-201: A Phase II/III Randomized Double-blind Placebo-controlled Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
Recruiting
99 years and younger
All
1 Location
Brief description of study
dosing of ABC008 in subjects with inclusion body myositis (IBM).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
08 Mar 2023.
Study ID: 853035
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting